Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nürnberg, Erlangen, Germany.
JAMA Dermatol. 2021 Sep 1;157(9):1066-1077. doi: 10.1001/jamadermatol.2021.2779.
Multiple interventions are available for the treatment of actinic keratosis (AK). However, most randomized clinical trials and meta-analyses focus on short-term efficacy outcomes.
To investigate and synthesize the long-term efficacy (≥12 months) of interventions for AK from parallel-arm randomized clinical trials.
Searches in MEDLINE, Embase, and Central were conducted from inception until April 6, 2020. The reference lists of the included studies and pertinent trial registers were hand searched. The study was completed February 27, 2021.
Two reviewers screened the titles and abstracts of 2741 records. Finally, 17 published reports (original studies and follow-up reports) referring to 15 independent randomized clinical trials with an overall sample size of 4252 patients were included.
Two reviewers independently extracted data on study, patient, and intervention characteristics. Network meta-analysis (NMA) of each outcome was conducted with a frequentist approach. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidance for NMA was used to assess the certainty of evidence. The revised Cochrane risk-of-bias tool for randomized clinical trials was used to evaluate the methodologic quality.
Participant complete clearance, participant partial clearance, and lesion-specific clearance were the outcomes, with each assessed at least 12 months after the end of treatment.
Data from 15 independent randomized clinical trials including 4252 patients were extracted and synthesized. Ten studies were included in an NMA for the outcome of participant complete clearance, with photodynamic therapy with aminolevulinate (ALA-PDT) showing the most favorable risk ratio (RR) compared with placebo (RR, 8.06; 95% CI, 2.07-31.37; GRADE, moderate), followed by imiquimod, 5% (RR, 5.98; 95% CI, 2.26-15.84; GRADE, very low), photodynamic therapy with methyl aminolevulinate (MAL-PDT) (RR, 5.95; 95% CI, 1.21-29.41; GRADE, low), and cryosurgery (RR, 4.67; 95% CI, 1.36-16.66; GRADE, very low). Similarly, ALA-PDT had the highest RR in the NMA for lesion-specific clearance (RR, 5.08; 95% CI, 2.49-10.33; GRADE, moderate). No NMA was possible for participant partial clearance owing to poor reporting of this outcome.
This systematic review and network meta-analysis found that therapy including ALA-PDT, imiquimod, 5%, MAL-PDT, and cryosurgery was associated with significant long-term efficacy in the NMA. This study provides data for a possible use in an evidence-based framework for selecting interventions with sustained lesion clearance.
有多种干预措施可用于治疗光化性角化病(AK)。然而,大多数随机临床试验和荟萃分析都侧重于短期疗效结果。
从平行臂随机临床试验中调查和综合 AK 的长期疗效(≥12 个月)。
从 MEDLINE、Embase 和中央数据库中进行了检索,检索时间从成立到 2020 年 4 月 6 日。纳入研究的参考文献列表和相关试验登记册也进行了手工检索。研究于 2021 年 2 月 27 日完成。
两名评审员筛选了 2741 条记录的标题和摘要。最终,纳入了 17 份发表的报告(原始研究和随访报告),涉及 15 项独立的随机临床试验,共有 4252 名患者。
两名评审员独立提取了研究、患者和干预措施特征的数据。采用似然法对每个结局进行了网络荟萃分析(NMA)。使用 NMA 的 Grading of Recommendations Assessment,Development,and Evaluation(GRADE)指南来评估证据的确定性。使用修订后的 Cochrane 随机临床试验偏倚风险工具来评估方法学质量。
参与者完全清除、参与者部分清除和病变特异性清除是结局,每个结局均在治疗结束后至少 12 个月进行评估。
共提取和综合了来自 15 项独立的随机临床试验的 4252 名患者的数据。有 10 项研究纳入了参与者完全清除结局的 NMA,与安慰剂相比,光动力疗法联合氨基酮戊酸(ALA-PDT)显示出最有利的风险比(RR)(RR,8.06;95%CI,2.07-31.37;GRADE,中度),其次是咪喹莫特 5%(RR,5.98;95%CI,2.26-15.84;GRADE,极低)、光动力疗法联合甲基氨基酮戊酸(MAL-PDT)(RR,5.95;95%CI,1.21-29.41;GRADE,低)和冷冻疗法(RR,4.67;95%CI,1.36-16.66;GRADE,极低)。同样,在病变特异性清除的 NMA 中,ALA-PDT 的 RR 最高(RR,5.08;95%CI,2.49-10.33;GRADE,中度)。由于该结局报告不佳,无法进行参与者部分清除的 NMA。
本系统评价和网络荟萃分析发现,包括 ALA-PDT、咪喹莫特 5%、MAL-PDT 和冷冻疗法在内的治疗方法在 NMA 中具有显著的长期疗效。本研究为基于证据的框架中选择具有持续病变清除的干预措施提供了数据。